A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.

Autor: Moustafa MA; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida., Ramdial JL; Department of Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsalatsanis A; Department of Internal Medicine, Research Methodology and Biostatistics Core, Office of Research, University of South Florida Morsani College of Medicine, Tampa, Florida., Khimani F; Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Dholaria B; Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Bojanini L; Stanford University School of Medicine, Palo Alto, California., Brooks TR; Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio., Zain J; Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, California., Bennani NN; Hematology, Mayo Clinic, Rochester, Minnesota., Braunstein Z; Department of Internal Medicine, Ohio State University Wexner Medical Columbus, Columbus, Ohio., Brammer JE; Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami, Miami, Florida., Jagadeesh D; Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio., Weng WK; Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, California., Kumar A; Department of Internal Medicine, Research Methodology and Biostatistics Core, Office of Research, University of South Florida Morsani College of Medicine, Tampa, Florida., Kharfan-Dabaja MA; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida., Ahmed S; Department of Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Murthy HS; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida. Electronic address: Murthy.hemant@mayo.edu.
Jazyk: angličtina
Zdroj: Transplantation and cellular therapy [Transplant Cell Ther] 2024 May; Vol. 30 (5), pp. 516.e1-516.e10. Date of Electronic Publication: 2024 Feb 29.
DOI: 10.1016/j.jtct.2024.02.021
Abstrakt: Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive type of peripheral T-cell lymphoma with median overall survival (OS) of approximately 1 year. Data on the effectiveness of hematopoietic cell transplantation (HCT) is limited, as is the choice between autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT) in the treatment of this disease. To evaluate the outcome of patients with HSTCL who underwent either auto-HCT or allo-HCT, we performed a multi-institutional retrospective cohort study to assess outcomes of HCT in HSTCL patients. Fifty-three patients with HSTCL were included in the study. Thirty-six patients received an allo-HCT and 17 received an auto-HCT. Thirty-five (66%) were males. Median age at diagnosis was 38 (range 2 to 64) years. Median follow-up for survivors was 75 months (range 8 to 204). The median number of prior lines of therapy was 1 (range 1 to 4). Median OS and progression-free survival (PFS) for the entire cohort were 78.5 months (95% CI: 25 to 79) and 54 months (95% CI: 18 to 75), respectively. There were no significant differences in OS (HR: 0.63, 95% CI: 0.28 to 1.45, P = .245) or PFS (HR: 0.7, 95% CI: 0.32 to 1.57, P = .365) between the allo-HCT and auto-HCT groups, respectively. In the allo-HCT group, the 3-year cumulative incidence of relapse was 35% (95% CI: 21 to 57), while 3-year cumulative incidence of NRM was 16% (95% CI: 7 to 35). In the auto-HCT group, the 3-year cumulative incidence of relapse and NRM were 43% (95% CI: 23 to 78) and 14% (95% CI: 4 to 52), respectively. Both Auto-HCT and Allo-HCT are effective consolidative strategies in patients with HSTCL, and patients should be promptly referred for HCT evaluation.
(Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: